The IL33/ST2 axis in Sjogren Syndrome in relation to disease activity

European Review for Medical and Pharmacological Sciences

Volumn 20, Issue 7, 2016, Pages 1295-1299

  Margiotta, D P E ^a   Navarini, L ^a   Vadacca, M ^a   Lo Vullo, M ^a   Pignataro, F ^a   Basta, F ^a   Afeltra, A ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Disease activity index; Interleukin 33; Sjogren's syndome; ST2

Indexed keywords

INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33; BIOLOGICAL MARKER; CYTOKINE; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPRESSION; FEMALE; HUMAN; INFORMED CONSENT; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SJOEGREN SYNDROME; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; BLOOD; DISEASE COURSE; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; BIOMARKERS; COHORT STUDIES; CYTOKINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; MALE; MIDDLE AGED; SJOGREN'S SYNDROME;

EID: 85017150567     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. VITALI C, BOMBARDIERI S, JONSSON R, MOUTSOPOULOS H, ALEXANDER EL, CARSONS SE, DANIELS TE, FOX PC, FOX RI, KASSAN SS, PILLEMER SR, TALAL N, WEISMAN NH AND THE EUROPEAN STUDY GROUP ON CLASSIFICATION CRITERIA FOR SJÖGREN'S SYNDROME. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558.
2. MAVRAGANI CP, NEZOS A, MOUTSOPOULOS NH. New advances in the classification, pathogenesis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 2013;25:623-629.
3. BRITO-ZERÓN P, RAMOS-CASALS M; AND EULAR-SS TASK FORCE GROUP. Advances in the understanding and treatment of systemic complications in Sjögren's syndrome. Curr Opin Rheumatol 2014;26:520-527.
4. NOCTURNE G, MARIETTE X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol 2013;9:544-556.
5. CORNEC D, JAMIN C, PERS JO. Sjögren's syndrome: where do we stand, and where shall we go? J Autoimmun 2014;51:109-114.
6. KRAMER JM. Early events in Sjögren's Syndrome pathogenesis: the importance of innate immunity in disease initiation. Cytokine 2014;67:92-101.
7. VOULGARELIS M, TZIOUFAS AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndrome. Nat Rev Rheumatol 2010;6:529-537.
8. LUCIANO N, VALENTINI V, CALABRÒ A, ELEFANTE E, VITALE A, BALDINI C, BARTOLONI E. One year in review 2015: Sjögren's syndrome. Clin Exp Rheumatol 2015;33:259-271.
9. PALMER G, GABAY C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011;7:321-329.
10. LIEW FY. IL-33: a Janus cytokine. Ann Rheum Dis 2012;71:101-104.
11. MAKRINIOTI H, TOUSSAINT M, JACKSON DJ, WALTON RP, JOHNSTON SL. Role of interleukin 33 in respiratory allergy and asthma. Lancet Respir Med 2014;2:226-237.
12. MOLOFSKY AB, SAVAGE AK, LOCKSLEY RM. Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity 2015;42:1005-1019.
13. MARTIN MU. Special aspects of interleukin-33 and the IL-33 receptor complex. Semin Immunol 2013;25:449-457.
14. WANG S, DING L, LIU SS, WANG C, LENG RX, CHEN GM, FAN YG, PAN HF, YE DQ. IL-33: a potential therapeutic target in autoimmune diseases. J Investig Med 2012;60:1151-1156.
15. AWADA A, NICAISE C, ENA S, SCHANDÉNÉ L, RASSCHAERT J, POPESCU I, GANGJI V, SOYFOO MS. Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome. Ann Rheum Dis 2014;73:1259-1263.
16. JUNG SM, LEE J, BAEK SY, LEE JH, LEE J, PARK KS, PARK SH, KIM HY, KWOK SK. The Interleukin 33/ST2 axis in patients with primary Sjögren syndrome: expression in serum and salivary glands, and the clinical association. J Rheumatol 2015;42:264-271.
17. PETRI M, ORBAI AM, ALARCÓN GS, GORDON C, MERRILL JT, FORTIN PR, BRUCE IN, ISENBERG D, WALLACE DJ, NIVED O, STURFELT G, RAMSEY-GOLDMAN R, BAE SC, HANLY JG, SÁNCHEZ-GUERRERO J, CLARKE A, ARANOW C, MANZI S, UROWITZ M, GLADMAN D, KALUNIAN K, COSTNER M, WERTH VP, ZOMA A, BERNATSKY S, RUIZIRASTORZA G, KHAMASHTA MA, JACOBSEN S, BUYON JP, MADDISON P, DOOLEY MA, VAN VOLLENHOVEN RF, GINZLER E, STOLL T, PESCHKEN C, JORIZZO JL, CALLEN JP, LIM SS, FESSLER BJ, INANC M, KAMEN DL, RAHMAN A, STEINSSON K, FRANKS AG JR, SIGLER L, HAMEED S, FANG H, PHAM N, BREY R, WEISMAN MH, MCGWIN G JR, MAGDER LS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-2686.
18. VITALI C, PALOMBI G, BALDINI C, BENUCCI M, BOMBARDIERI S, COVELLI M, DEL PAPA N, DE VITA S, EPIS O, FRANCESCHINI F, GERLI R, GOVONI M, BONGI SM, MAGLIONE W, MIGLIARESI S, MONTECUCCO C, OREFICE M, PRIORI R, TAVONI A, VALESINI G. Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 2007;56:2223-2231.
19. URIBE AG, VILÁ LM, MCGWIN G JR, SANCHEZ ML, REVEILLE JD, ALARCÓN GS. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004;31:1934-1940.
20. GIGANTE A, AMOROSO D, FERRI F, GIANNI C, COPPOLINO G, PAPA A, AMOROSO A. Systemic lupus erythematosus and renal involvement: which role of citokines expression? Eur Rev Med Pharmacol Sci 2006;10:223-228.
21. GIGANTE A, GASPERINI ML, AFELTRA A, BARBANO B, MARGIOTTA D, CIANCI R, DE FRANCESCO I, AMOROSO A. Cytokine expression in SLE nephritis. Eur Rev Med Pharmacol Sci 2011;15:15-24.